Cao YW, et al. - Authors evaluated the associations of monocarboxylate transporter 1 (MCT1) and MCT4, 2 critical transporters for glycolytic metabolism, with various clinicopathological parameters as well as survival of patients with clear cell renal cell carcinoma (ccRCC) and those treated with vascular endothelial growth factor receptor (VEGFR) inhibitors. For patients with ccRCC or those receiving targeted therapy, MCT1 and MCT4 were prognostic biomarkers. Reduced progression-free survival was predicted by high expression of these 2 proteins in these patients. No significant correlation of MCT1 or MCT4 expression with sex, age, tumour diameter, microvascular density, tumour staging, pathological Furmann grade, or MSKCC was noted by the experts.